# A Study of Trabectedin in Patients With Advanced Ovarian Cancer

> **NCT00050414** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 147 (actual)

## Conditions studied

- Ovarian Neoplasms
- Endocrine Gland Neoplasms
- Neoplasms by Site
- Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Diseases, Female

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00050414
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2013-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050414, "A Study of Trabectedin in Patients With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00050414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*